JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $56 to $63.
Read original at benzingaStocks · News reference
Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026
FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time through September 30,
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 21, 2026, 1:11 PM
- Checked
- Aug 21, 2026, 1:11 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping the September 30 approval date on schedule.
Read original at benzingaWedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $58 price target.
Read original at benzinga